ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 134 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.20 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,118,607 | -27.8% | 55,763 | +1.6% | 0.00% | -100.0% |
| Q2 2023 | $1,548,983 | +129.3% | 54,909 | +39.8% | 0.00% | – |
| Q1 2023 | $675,461 | -12.0% | 39,271 | +3.0% | 0.00% | – |
| Q4 2022 | $767,596 | -6.0% | 38,113 | +1.0% | 0.00% | – |
| Q3 2022 | $817,000 | -18.1% | 37,720 | +6.3% | 0.00% | – |
| Q2 2022 | $998,000 | -15.9% | 35,491 | +38.1% | 0.00% | – |
| Q1 2022 | $1,186,000 | +40.4% | 25,700 | +155.7% | 0.00% | – |
| Q4 2021 | $845,000 | +44.4% | 10,050 | +14.4% | 0.00% | – |
| Q3 2021 | $585,000 | +142.7% | 8,788 | +93.3% | 0.00% | – |
| Q2 2021 | $241,000 | +32.4% | 4,546 | +8.5% | 0.00% | – |
| Q1 2021 | $182,000 | -14.2% | 4,191 | +2.4% | 0.00% | – |
| Q4 2020 | $212,000 | +371.1% | 4,093 | +199.9% | 0.00% | – |
| Q3 2020 | $45,000 | -44.4% | 1,365 | -18.7% | 0.00% | – |
| Q2 2020 | $81,000 | – | 1,679 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |